New cancer drug trial seeks to control advanced tumors
NCT ID NCT06226766
Summary
This early-stage study tested a new combination drug called JSKN033 in patients with advanced solid tumors that have spread and express the HER2 protein. The trial aimed to find a safe dose and see if the drug could help control cancer growth. It involved a small group of patients whose cancers had not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scientia Clinical Research
Randwick, New South Wales, 2031, Australia
Conditions
Explore the condition pages connected to this study.